Kürktschiev D, Subat S, Adler D, Schentke K U
Medizinische Akademie Carl Gustav Carus, Abteilung für Gastroenterologie, Dresden, Germany.
J Hepatol. 1993 Jul;18(3):373-7. doi: 10.1016/s0168-8278(05)80284-3.
Peripheral blood lymphocytes of 22 patients with primary biliary cirrhosis under ursodeoxycholic acid therapy were examined for selected lymphocyte activation markers. The percentage of dipeptidyl peptidase IV positive Peripheral blood lymphocytes of primary biliary cirrhosis patients by using immune- and enzyme-histochemical staining was found to be low (5-12%), with healthy controls exhibiting a normal range of 18-27%. After pokeweed mitogen stimulation in vitro the interleukin-2 production by peripheral blood lymphocytes in primary biliary cirrhosis patients was significantly decreased (3.135 pg/ml mean value), compared to healthy subjects (61.167 pg/ml mean value). After 4-20 weeks ursodeoxycholic acid treatment the dipeptidyl peptidase IV expression and IL-2 production were normalised. These results provide evidence for the immunomodulating effect of ursodeoxycholic acid.
对22例接受熊去氧胆酸治疗的原发性胆汁性肝硬化患者的外周血淋巴细胞进行了特定淋巴细胞活化标志物检测。通过免疫组织化学和酶组织化学染色发现,原发性胆汁性肝硬化患者二肽基肽酶IV阳性外周血淋巴细胞的百分比很低(5%-12%),而健康对照者的正常范围为18%-27%。体外经商陆有丝分裂原刺激后,原发性胆汁性肝硬化患者外周血淋巴细胞产生的白细胞介素-2显著减少(平均值为3.135 pg/ml),而健康受试者的平均值为61.167 pg/ml。经过4-20周的熊去氧胆酸治疗后,二肽基肽酶IV的表达和白细胞介素-2的产生恢复正常。这些结果为熊去氧胆酸的免疫调节作用提供了证据。